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Background: The aim of the present study was to determine the feasibility and safety of performing
diagnostic laparoscopy (DLS) routinely in patients with suspicion of colorectal peritoneal metastases
(PM) to evaluate suitability for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
(CRS+HIPEC).
Methods: Data for consecutive patients who underwent DLS between 2012 and 2018 were extracted
retrospectively from an institutional database. The primary outcome was the degree of visibility of the
abdominal cavity during DLS. Good laparoscopic evaluation of the abdominal cavity was defined as visi-
bility of at least the regions of the diaphragm, pelvis and small bowel. Secondary outcomes were reasons
for perioperative exclusion for CRS+HIPEC, major postoperative complications (Clavien–Dindo grade
III or above) and difference in overall survival (OS) between patients deemed suitable or unsuitable for
CRS+HIPEC. Kaplan–Meier analyses were performed.
Results: Some 184 patients were analysed. Good laparoscopic evaluation was possible in 138 patients
(75⋅0 per cent), and 24 (13⋅0 per cent) had conversion to an open procedure. Ninety-three patients (50⋅5
per cent) were excluded for CRS+HIPEC, most commonly because of absence of colorectal PM (34
patients, 37 per cent) or extensive disease (Peritoneal Cancer Index 20 or above) (33 patients, 35 per
cent). Major complications occurred in five patients (2⋅7 per cent), with no postoperative deaths. Median
OS was significantly decreased in patients who were excluded due to extensive disease (14 (95 per cent c.i.
10 to 18) months) compared with patients suitable for CRS+HIPEC (36 (27 to 45) months) (P< 0⋅001).
Conclusion: Routinely performingDLS in patients with suspicion of colorectal PM to evaluate suitability
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Introduction
Patients with resectable peritoneal metastases (PM)
from colorectal cancer can be treated with cytoreduc-
tive surgery combined with hyperthermic intraperitoneal
chemotherapy (CRS+HIPEC)1–4. This abdominal pro-
cedure begins with surgical removal of all visible tumour
tissue followed by perfusion of the peritoneal cavity with
heated chemotherapy to eliminate remaining microscopic
disease5. The most powerful prognostic factors for sur-
vival after CRS+HIPEC are the extent of peritoneal
disease (measured with the Peritoneal Cancer Index (PCI))
and completeness of the performed cytoreduction (mea-
sured with the Completeness of Cytoreduction (CC)
© 2019 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd BJS Open 2019; 3: 812–821
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Diagnostic laparoscopy for colorectal peritoneal metastases 813
score))2,6–8. CRS+HIPEC can be performed with cura-
tive intent only in patients with colorectal PM with a PCI
of less than 20 in whom a (nearly) complete cytoreduction
can be achieved (for example CC-0, no visible residual
disease, or CC-1, residual tumour deposits smaller than
2⋅5mm)3,7,9–11.
Current preoperative imaging modalities fail to estimate
the PCI in order to predict the possibility of achieving a
complete cytoreduction12–14. Direct visualization of the
abdominal cavity and its contents, such as the small bowel,
seems to be the only reliable method to assess PCI and
tumour resectability. Up to 50 per cent of patients with
colorectal PM are excluded for CRS+HIPEC directly on
exploratory laparotomy15–17. Identification at an earlier
stage in patients for whom CRS+HIPEC is not suit-
able could spare them the morbidity of an unnecessary
laparotomy.
Direct visualization can also be achieved with diag-
nostic laparoscopy (DLS), to evaluate the presence and
resectability of colorectal PM. Some argue that adhesions
from the cancer or previous abdominal surgery impede
optimal visualization during DLS, which could result in
underestimation of the PCI and an increased rate of intra-
operative and postoperative complications. In contrast,
seven retrospective studies15–21 concluded that DLS is a
safe, feasible and accurate staging tool for assessing tumour
burden in patients with PM. Therefore, several institutions
worldwide perform DLS routinely in patients with PM
to investigate their presence and resectability. However,
current publications on this subject have involved small
series of patients with PM from a variety of primary
tumour types and, most importantly, DLS was used in a
mostly selective way and not incorporated into a standard
preoperative workup for CRS+HIPEC.
The aim of the present study was to determine the feasi-
bility and safety of performingDLS routinely in all patients
with suspicion of colorectal PM to evaluate suitability for
CRS+HIPEC, and to investigate reasons for perioperative
exclusion for CRS+HIPEC.
Methods
Data for all consecutive patients with suspicion of colorec-
tal PM, based on recent imaging or a surgical procedure,
who had DLS to examine the presence and extent of
peritoneal disease between January 2012 and August 2018
were extracted retrospectively from a prospectively main-
tained institutional database. The study was approved by
the Institutional Ethics Committee of University Medical
Centre Groningen (METc 201800395).
Preoperative evaluation and staging
All patients had a standard preoperative assessment to
confirm the presence of colorectal PM and to evaluate
eligibility for CRS+HIPEC. All were staged by thoracic,
abdominal and pelvic CT. Patients with suspicion of col-
orectal PM who might be a candidate for CRS+HIPEC
routinely underwent DLS to confirm the diagnosis
of colorectal PM and to evaluate resectability of the
metastases.
A multidisciplinary team consisting of a radiologist,
gastroenterologist, medical oncologist and oncological
surgeons then determined eligibility for CRS+HIPEC
according to the preoperative assessment. Contraindi-
cations to CRS+HIPEC included: moderate or severe
co-morbidity (ASA score above III); extra-abdominal
metastases; massive disease involvement of the small bowel
or its mesentery; extensive peritoneal disease (PCI 20 or
above); unresectable primary tumour; invasive growth into
the retroperitoneal space; and Eastern Cooperative Oncol-
ogy Group performance status greater than 2. Patients
with no colorectal PM during DLS were also excluded
from CRS+HIPEC.
Laparoscopic evaluation
Under general anaesthesia, a pneumoperitoneum was
established using an optical trocar. The site of first port
placement during DLS was based on imaging and clinical
findings of the patient. The 30∘ laparoscope was intro-
duced through an umbilical port. One or two additional
operative trocars were positioned on the left and right side
of the optical trocar under direct vision. Adhesiolysis was
performed minimally. All visible areas of the peritoneal
cavity were reviewed systematically. In all patients the
laparoscopic PCI and possibility of performing a complete
cytoreduction were determined and recorded in the oper-
ation report. Cytology samples and biopsies were taken as
indicated.When the tumour size was unacceptably large or
there was unresectable disease at DLS, palliative surgery
was performed at the surgeon’s discretion. The main
reasons for perioperative exclusion in patients deemed
unsuitable for CRS+HIPEC were noted in the medical
record.
Cytoreductive surgery with hyperthermic
intraperitoneal chemotherapy
Each CRS+HIPEC procedure was started with an
exploratory laparotomy. CRS was performed only when
the colorectal PM were deemed to be completely
resectable, whereas HIPEC was performed only when
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 812–821
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Age (years)* 65 (58–70) 65 (54–69) 64 (56–71) 67 (60–70) 74 (63–76) 0⋅021‡
Sex ratio (F :M) 83 : 101 45 : 46 12 : 17 20 : 34 6 : 4 0⋅368
BMI (kg/m2)* 26⋅3 (24⋅1–29⋅0) 26⋅5 (24⋅3–30⋅4) 27⋅2 (25⋅4–28⋅3) 26⋅2 (3⋅5–28⋅6) 25⋅9 (23⋅6–31⋅3) 0⋅811‡
ASA ﬁtness grade 0⋅079
I 22 (12⋅0) 10 (11) 4 (19) 7 (13) 1 (10)
II 139 (75⋅5) 72 (79) 22 (76) 41 (76) 4 (40)
III 23 (12⋅5) 9 (10) 3 (10) 6 (11⋅1) 5 (50)
Co-morbidity
Diabetes 19 (10⋅3) 8 (9) 2 (7) 9 (17) 0 (0) 0⋅238
Cardiovascular disease 28 (15⋅2) 12 (13) 4 (14) 9 (17) 3 (30) 0⋅336
Pulmonary disease 19 (10⋅3) 9 (10) 5 (17) 4 (7) 1 (10) 0⋅536
Previous surgery for colorectal cancer 142 (77⋅2) 84 (92) 23 (79) 27 (50) 8 (80) 0⋅006
Primary tumour 0⋅557
Appendix 9 (4⋅9) 7 (8) 1 (3) 1 (2) 0 (0)
Right colon 68 (37⋅0) 27 (30) 10 (34) 27 (50) 4 (40)
Transverse colon 10 (5⋅4) 6 (7) 0 (0) 3 (6) 1 (10)
Left colon 16 (8⋅7) 14 (15) 1 (3) 0 (0) 1 (10)
Sigmoid 53 (28⋅8) 26 (29) 10 (34) 14 (26) 3 (30)
Rectum 23 (12⋅5) 11 (12) 5 (17) 7 (13) 0 (0)
Rectosigmoid 5 (2⋅7) 0 (0) 2 (7) 2 (4) 1 (10)
Signet cell histology 19 (10⋅3) 8 (9) 0 (0) 11 (20) 0 (0) < 0⋅001
T category of primary tumour n=154 n=83 n=27 n=35 n=9 0⋅400
≤3 70 (45⋅5) 38 (46) 12 (44) 14 (40) 6 (67)
4 84 (54⋅5) 45 (54) 15 (56) 21 (60) 3 (33)
N category of primary tumour n=151 n=83 n=27 n=32 n=9 < 0⋅001
0 48 (31⋅8) 24 (29) 14 (52) 7 (22) 3 (33) 0⋅006
1 46 (30⋅5) 26 (31) 10 (37) 9 (28) 1 (11) 0⋅157
2 57 (37⋅7) 33 (40) 3 (11) 16 (50) 5 (56) 0⋅034
Preoperative imaging
CT 171 (92⋅9) 79 (87) 29 (100) 54 (100) 9 (90) 0⋅035
MRI 33 (17⋅9) 13 (14) 7 (24) 11 (20) 2 (20) 0⋅501
PET 72 (39⋅1) 35 (38) 15 (52) 19 (35) 3 (30) 0⋅030
Onset of suspicion of PM n=183 n=90 0⋅143
Synchronous 99 (54⋅1) 41 (46) 15 (52) 38 (70) 5 (50)
Metachronous 84 (45⋅9) 49 (54) 14 (48) 16 (30) 5 (50)
Suspicion of PM based on 0⋅796
Preoperative imaging 130 (70⋅7) 53 (58) 24 (83) 43 (80) 8 (80)
Recent surgical procedure 25 (13⋅6) 17 (19) 2 (7) 5 (9) 1 (10)
Perforated tumour 2 (1⋅1) 1 (1) 1 (3) 0 (0) 0 (0)
Preoperative imaging + surgical procedure 26 (14⋅1) 19 (21) 2 (7) 6 (11) 1 (10)
Preoperative imaging + perforated tumour 1 (0⋅5) 1 (1) 0 (0) 0 (0) 0 (0)
Liver metastases 21 (11⋅4) 10 (11) 1 (3) 9 (17) 1 (10) 0⋅344
Lung metastases 5 (2⋅7) 1 (1) 0 (0) 4 (7) 0 (0) 0⋅090
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r). CRS, cytoreductive surgery; HIPEC, hyperthermic
intraperitoneal chemotherapy; PM, peritoneal metastases. †χ2 test, except ‡Kruskal–Wallis H test.
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 812–821
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Table 2 Reasons for perioperative exclusion for cytoreductive
surgery with hyperthermic intraperitoneal chemotherapy during
diagnostic laparoscopy
No. of patients (n=93)




No signs of colorectal PM 34 (37)
Signs of extensive disease
PCI>20 33 (35)
PCI probably too high during open procedure* 6 (6)
Widespread colorectal PM in bowel/mesentery 7 (8)
Rapid progression of disease 7 (8)
Indication for neoadjuvant therapy 5 (5)
Liver metastases 4 (4)
Lung metastases 5 (5)
Unresectable primary tumour 1 (1)
Patient characteristics
Patient preference 7 (8)
Co-morbidity 5 (5)
Patient condition 3 (3)
Patient age 3 (3)
Severe complications after DLS 3 (3)
Tumour biology (signet cell histology) 2 (2)
Values in parentheses are percentages. *Peritoneal Cancer Index (PCI)
during diagnostic laparoscopy (DLS) below 20, but estimated as above 20
during exploratory laparotomy. PM, peritoneal metastases.
there was complete or nearly complete cytoreduction.
CRS+HIPEC was performed according to the stan-
dardized Dutch HIPEC protocol22. The CC score was
classified at the end of the cytoreduction: CC-0, no resid-
ual tumour visible or palpable in the peritoneal cavity;
CC-1, residual tumour deposits smaller than 2⋅5mm;
CC-2, residual tumour between 2⋅5mm and 2⋅5 cm; and
CC-3, residual tumour larger than 2⋅5 cm or a confluence
of nodules23. After cytoreduction, HIPEC was performed
in patients with CC-0 (complete) or CC-1 (nearly com-
plete) cytoreduction according to the open Coliseum
technique with mitomycin C (35 kg/m2) for 90min at
40–41∘C.
Follow-up
Physical examination and carcinoembryonic antigen (CEA)
measurements were performed on a 3-monthly basis for
at least 4 years. When disease recurrence was suspected
(for example, clinical symptoms or increase in CEA level),
CT of the thorax and abdomen was performed, with tissue
biopsies in selected patients.
Data collection
Data on patient characteristics, tumour characteristics,
operative details, postoperative morbidity and mortality,
and overall survival (OS) were collected prospectively. Data
on perioperative reasons for exclusion for CRS+HIPEC
were obtained retrospectively by reviewing the digital med-
ical records.
Primary and secondary outcomes
The primary outcome was the degree of visibility of the
abdominal cavity during DLS: grade I, visibility of two or
fewer abdominopelvic regions; grade II, visibility of three
to eight abdominopelvic regions; grade III, visibility of
at least the diaphragm, pelvis and small bowel regions;
or grade IV, visibility of all 13 abdominopelvic regions.
Grade III or IV was deemed necessary for adequate judge-
ment of the extent of disease, and therefore defined as a
good laparoscopic evaluation of the abdominal cavity. Sec-
ondary outcomes were the proportion of patients excluded
for CRS+HIPEC, perioperative reasons for exclusion for
CRS+HIPEC, major postoperative complications, and
OS in suitable and unsuitable patients. Major postoperative
complications were defined as grade III or above accord-
ing to the Clavien–Dindo classification system24. OS was
defined as the time between DLS and death, or date of last
follow-up in censored cases.
Statistical analysis
All statistical analyses were conducted using SPSS®
Statistics version 24.0 (IBM, Armonk, New York, USA).
Continuous variables with a normal distribution are given
as mean(s.d.) values, and those without a normal distri-
bution as median (i.q.r.) values. Categorical variables are
reported as numbers with percentages. Patient and tumour
characteristics were compared and analysed using the χ2
test. The Kruskal–Wallis H test was used for continuous
variables. Kaplan–Meier survival analyses were performed
to describe OS for the different groups of patients. All tests
were performed two-sided and P< 0⋅050 was considered
statistically significant.
Results
Data for all 184 patients with suspicion of colorectal
PM who had undergone DLS between January 2012 and
August 2018 were analysed. During DLS, 91 patients (49⋅5
per cent) were deemed suitable for CRS+HIPEC, and
93 patients (50⋅5 per cent) were rejected for the proce-
dure. The group of 93 patients deemed unsuitable for
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 812–821
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Interval from primary surgery to DLS (months)* 11 (2–23) 12 (2–23) 6 (6–33) 6 (1–20) 11 (2–25) 0⋅397‡
Interval from suspicion of PM to DLS (months)* 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–3) 0⋅158‡
Grade of visibility n=180 n=89 n=52 0⋅008
I (very poor) 25 (13⋅8) 13 (15) 5 (17) 4 (8) 3 (30) 0⋅220
II (poor) 17 (9⋅4) 6 (7) 4 (14) 3 (6) 4 (40) 0⋅003
III (good) 23 (12⋅8) 11 (12) 2 (7) 9 (17) 1 (10) 0⋅623
IV (excellent) 115 (63⋅9) 59 (66) 18 (62) 36 (69) 2 (20) 0⋅040
Conversion rate 24 (13⋅0) 15 (16) 3 (10) 5 (9) 1 (10) 0⋅398
PCI at DLS n=162 n=78 n=28 n=51 n=5 <0⋅001
0–5 84 (51⋅9) 43 (55) 28 (100) 10 (20) 3 (60) <0⋅001
6–10 23 (14⋅2) 19 (24) 0 (0) 3 (6) 1 (20) 0⋅006
11–15 11 (6⋅8) 9 (12) 0 (0) 1 (2) 1 (20) 0⋅100
16–20 14 (8⋅6) 7 (9) 0 (0) 7 (14) 0 (0) 0⋅397
21–25 13 (8⋅0) 0 (0) 0 (0) 13 (25) 0 (0) <0⋅001
>25 17 (10⋅5) 0 (0) 0 (0) 17 (33) 0 (0) <0⋅001
Length of hospital stay (days)* 2 (1–4) 2 (2–3) 3 (1–5) 2 (1–4) 2 (1–14) 0⋅839‡
Clavien–Dindo complication grade 17 (9⋅2) 4 (4) 4 (14) 6 (11) 3 (30) 0⋅027
I 3 (1⋅6) 0 (0) 1 (3) 2 (4) 0 (0) 0⋅293
II 7 (3⋅8) 4 (4) 0 (0) 2 (4) 1 (10) 0⋅516
III 5 (2⋅7) 0 (0) 1 (3) 3 (6) 1 (10) 0⋅030
Complication 0⋅040
Ileus 4 (2⋅2) 0 (0) 0 (0) 3 (6) 1 (10) 0⋅038
Wound infection 3 (1⋅6) 1 (1) 1 (3) 0 (0) 1 (10) 0⋅211
Gastroparesis 1 (0⋅5) 0 (0) 0 (0) 1 (2) 0 (0) 0⋅490
Bowel perforation 1 (0⋅5) 0 (0) 1 (3) 0 (0) 0 (0) 0⋅146
Intra-abdominal abscess 1 (0⋅5) 1 (1) 0 (0) 0 (0) 0 (0) 0⋅795
Urinary tract infection 1 (0⋅5) 1 (1) 0 (0) 0 (0) 0 (0) 0⋅795
Pneumonia 1 (0⋅5) 0 (0) 0 (0) 0 (0) 1 (10) 0⋅001
Myocardial infarction 1 (0⋅5) 0 (0) 1 (3) 0 (0) 0 (0) 0⋅146
Decompensated liver cirrhosis 1 (0⋅5) 0 (0) 0 (0) 1 (2) 0 (0) 0⋅490
Electrolyte disorder 1 (0⋅5) 0 (0) 0 (0) 1 (2) 0 (0) 0⋅490
Bacteraemia (cause unknown) 1 (0⋅5) 1 (1) 0 (0) 0 (0) 0 (0) 0⋅795
Enterocutaneous fistula 1 (0⋅5) 0 (0) 1 (3) 0 (0) 0 (0) 0⋅146
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r). CRS, cytoreductive surgery; HIPEC, hyperthermic
intraperitoneal chemotherapy; DLS, diagnostic laparoscopy; PM, peritoneal metastases; PCI, Peritoneal Cancer Index. †χ2 test, except ‡Kruskal–Wallis
H test.
CRS+HIPEC was very heterogeneous, and for further
analyses was subdivided into the following categories: no
indication for CRS+HIPEC because of absence of col-
orectal PM (29 patients); signs of extensive disease (54); and
other reason for perioperative exclusion10.
Table 1 provides an overview of patient and tumour char-
acteristics for the entire cohort, and a comparison of these
characteristics between patients suitable for CRS+HIPEC
and patients who were not suitable. Patients who were
unsuitable for CRS+HIPEC owing to signs of exten-
sive disease presented more frequently with signet ring
cell histology compared with those who were suitable
for CRS+HIPEC (20 versus 9 per cent respectively;
P< 0⋅001). Patients with no indication for CRS+HIPEC
were less likely to have an N2 status than those who
were suitable for CRS+HIPEC (11 versus 40 per cent;
P= 0⋅034). The median age of patients who were not suit-
able for CRS+HIPEC for other reasons was greater than
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 812–821
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Table 4 Treatment received after diagnostic laparoscopy in





Open CRS+HIPEC 75 (82)
Open–close procedure 16 (18)
Reason for open–close procedure
PCI too high 9 (56)
Small bowel involvement 2 (13)
Unresectable primary tumour 4 (25)
Liver metastases 1 (6)












Stoma after HIPEC 40 (44)
Stoma type
Double-barrel ileostomy 2 (5)
Ileostomy 7 (18)
Double-barrel colonostomy 3 (8)
Colonostomy 28 (70)
Blood loss (ml)† 600 (200–1188)





Length of hospital stay (days)† 19 (13–27)
Clavien–Dindo complication grade
No complication 29 (32)
I–II 31 (34)
≥ III 31 (34)
Reoperation 16 (18)
Adjuvant chemotherapy 26 (29)
*With percentages in parentheses unless indicated otherwise; †values are
median (i.q.r.).HIPEC, hyperthermic intraperitoneal chemotherapy; CRS,
cytoreductive surgery; PCI, Peritoneal Cancer Index; CC, Completeness
of Cytoreduction.
that of patients who were suitable for CRS+HIPEC
(74 versus 65 years; P= 0⋅021). Other baseline char-
acteristics were similar between the four groups of
patients.
Table 5 Treatment received after diagnostic laparoscopy in




No indication for CRS+HIPEC n= 29
No/palliative treatment 7 (24)
Systemic chemotherapy 3 (10)
Combined treatments 5 (17)
Curative surgery 14 (48)
Not suitable for CRS+HIPEC due to extensive
disease
n=54
No/palliative treatment 13 (24)
Systemic chemotherapy 20 (37)
Radiotherapy 2 (4)
Combined treatments 9 (17)
Unknown 10 (19)
Not suitable for CRS+HIPEC for other reason n= 10
No/palliative treatment 4 (40)
Palliative surgery 2 (20)
Systemic chemotherapy 1 (10)
Combined treatments 1 (10)
Unknown 2 (20)
Values in parentheses are percentages. CRS, cytoreductive surgery;
HIPEC, hyperthermic intraperitoneal chemotherapy.
Perioperative reasons for exclusion
for cytoreductive surgery with hyperthermic
intraperitoneal chemotherapy
Table 2 presents an overview of the reasons for perioper-
ative exclusion of the 93 patients (50⋅5 per cent) deemed
unsuitable for CRS+HIPEC. The reasons can be divided
into five categories: absence of colorectal PM; signs of
extensive disease; patient characteristics; severe compli-
cations after DLS; and tumour biology. In the majority
of the patients (65 per cent) only one reason resulted in
exclusion for CRS+HIPEC, whereas for fewer patients
two (28 per cent) or three (8 per cent) reasons led to
the exclusion. The most common perioperative reasons
for exclusion for CRS+HIPEC were: absence of colorec-
tal PM in 34 patients (37 per cent) and extensive peri-
toneal disease (PCI 20 or above) in 33 patients (35 per
cent). Other signs of extensive disease (widespread colorec-
tal PM in the small bowel, unresectable primary tumour,
liver or lung metastases, or an indication for neoadjuvant
chemotherapy) were present in 35 patients (38 per cent).
Patient characteristics were less frequently the periopera-
tive reason for exclusion for CRS+HIPEC: age in three
patients (3 per cent), poor patient condition in three (3 per
cent) and presence of severe co-morbidity in five patients
(5 per cent).
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 812–821
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Visibility of abdominal cavity during diagnostic
laparoscopy
Grade III or IV visibility of the abdominal cavity was pos-
sible in 138 of the 184 patients (75⋅0 per cent) (Table 3).
In 24 patients (13⋅0 per cent) DLS was converted to an
open procedure because of an inadequate laparoscopic
overview. Grade of visibility of the abdominal cavity dur-
ing DLS was not significantly different between patients
who were suitable and those who were not suitable for
CRS+HIPEC due to absence of colorectal PM or exten-
sive disease (P= 0⋅807). In the small group of patients who
were not suitable for CRS+HIPEC for other reasons, the
grade of visibility of the abdominal cavity was poor overall
(7 of 10, 70 per cent; P= 0⋅008).
Surgical morbidity and mortality
Table 3 presents postoperative morbidity rates after DLS,
by type and severity according to the Clavien–Dindo
classification system24. Major postoperative complications
occurred in five patients (2⋅7 per cent), who were all
deemed not suitable for CRS+HIPEC. Three patients
(1⋅6 per cent) with symptoms of preoperative obstruction
received direct palliative surgery during DLS without any
subsequent clinical improvement. In one morbidly obese
patient, a widespread haematoma of the abdominal wall
was infected after DLS and required surgical evacuation at
three different time points. In the fifth patient, myocardial
infarction was diagnosed immediately after DLS. Follow-
ing percutaneous coronary intervention, the patient recov-
ered successfully within 7 days.
Treatment strategies after diagnostic laparoscopy
The different treatments that patients received after DLS
are presented in Tables 4 and 5 according to suitability
for CRS+HIPEC. Only 75 of the 91 patients (82 per
cent) deemed suitable for CRS+HIPEC eventually under-
went the full procedure. The remaining 16 patients (18
per cent) had an open–close procedure after exploratory
laparotomy (non-therapeutic laparotomy), due to a high
PCI (9 patients), excessive involvement of the small bowel
(2), unresectable primary tumour (4) or liver metastases (1).
In retrospect, good or excellent laparoscopic evaluation of
the abdominal cavity during DLS had been possible in 12
of these 16 patients. In the remaining four patients it was
not possible to investigate all abdominopelvic regions but
it was estimated that the PCI would probably be below 20.
In patients deemed unsuitable for CRS+HIPEC, treat-
ment strategy depended on the perioperative reason(s) for
exclusion (Table 5). Fourteen of the 29 patients (48 per cent)
who had a primary tumour in situ with no colorectal PM
had surgery with curative intent. Most patients with no
primary tumour in situ did not receive any additional treat-
ment (7 patients, 24 per cent). During a median follow-up
of 16 (95 per cent c.i. 14 to 28) months, four of these 29
Fig. 1 Kaplan–Meier survival curves according to suitability and different reasons for perioperative exclusion for cytoreductive surgery






































Suitable for CRS+HIPEC 
No CRS+HIPEC  indication
Not suitable for CRS+HIPEC 
due to extensive disease
Not suitable for CRS+HIPEC 
 for other reason
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; DLS, diagnostic laparoscopy.
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patients (14 per cent) developed additional colorectal PM,
diagnosed in only two patients (7 per cent) within 6months
after DLS.
In the 54 patients unsuitable for CRS+HIPEC with
signs of extensive disease, palliative treatment strate-
gies consisted of comfort care (24 per cent), palliative
chemotherapy (37 per cent), radiotherapy (4 per cent) or
a combination of treatments (17 per cent). The majority
of patients who were not suitable for CRS+HIPEC for
other reasons received only comfort care (40 per cent).
Survival outcomes
Fig. 1 shows the median OS after DLS between patients
who were suitable for CRS+HIPEC and those who were
not suitable owing to the absence of colorectal PM, signs
of extensive disease, or other reasons for perioperative
exclusion. Median OS for patients deemed suitable for
CRS+HIPEC was 36 (95 per cent c.i. 27 to 45) months,
and that the three subgroups of patients deemed unsuitable
was 49 (40 to 60), 14 (10 to 18) and 24 (9 to 38) months
respectively (P< 0⋅001).
Discussion
In this observational study of 184 consecutive patients with
suspected colorectal PM, routinely performed laparoscopic
evaluation of the abdominal cavity was possible in the
majority of patients, with a low risk of major postopera-
tive morbidity. The study demonstrates that patients with
extensive disease can be spared an unnecessary laparotomy.
The extent of peritoneal disease (PCI) and the possibility
of achieving a complete cytoreduction are the most pow-
erful prognostic factors for survival after CRS+HIPEC,
and as current preoperative imaging modalities fail to pre-
dict PCI and complete cytoreduction, direct visualization
of the abdominal cavity appears to be the only reliable way
to assess both prognostic factors. To spare patients themor-
bidity of a laparotomy, the presence and resectability of col-
orectal PM could be evaluated by DLS as part of a two-step
approach. In this study, good or excellent laparoscopic eval-
uation of the abdominal cavity was possible in 75⋅0 per cent
of patients with suspected colorectal PM, despite the fact
that 83⋅7 per cent of these patients had a history of previ-
ous abdominal surgery. Major postoperative complications
occurred in only five patients (2⋅7 per cent), with no post-
operative deaths.
Comparison of the main results of the present study with
those from the seven previously published retrospective
studies15–21 on the value of DLS in the preoperative
workup for CRS+HIPEC is challenging. There are
striking differences in patient populations, tumour types,
definitions of a good laparoscopic evaluation of the
abdominal cavity, and the indications for performing DLS
or CRS+HIPEC.None of the other studies focused solely
on patients with suspicion of PM of colorectal origin; three
to nine primary tumour types were included per study. The
number of patients with suspected colorectal PM in these
studies ranged from 11 to 74. In most studies, it was not
possible to subtract the data from patients with colorectal
PM from the entire cohort. Only three studies15,17,19
made use of DLS as part of a two-step approach for
CRS+HIPEC. In these three studies, complete laparo-
scopic evaluation according to the PCI scoring system was
possible in 73–86 per cent of the patients with PM. DLS
resulted in 28–57 per cent of the patients being excluded
for CRS+HIPEC. These results are in line with those of
the present study. All studies used different definitions of
a good laparoscopic evaluation of the abdominal cavity,
and three studies gave no definition at all. Only von Bre-
itenbuch and colleagues20 used a definition similar to that
used in the present study, resulting in a good laparoscopic
evaluation in 88 per cent of patients with no history of
previous abdominal surgery and in 70 per cent of those
with such a history. Postoperative complication rates from
the seven retrospective studies15–21 ranged between 0 and
2 per cent. These studies included only patients without
palliative surgery during DLS, and for this specific group
the results of the present study are comparable.
Another important finding of the present study was the
unexpectedly high rate (50⋅5 per cent) of patients who were
potential candidates for CRS+HIPEC according to pre-
operative imaging, but were eventually deemed not suit-
able for CRS+HIPEC during DLS. On the one hand this
reflects the low validity of imaging for colorectal PM to
predict the presence and extent of peritoneal disease, and
on the other hand it supports the added value of DLS
before CRS+HIPEC; almost half of the patients with sus-
picion of colorectal PM were spared unnecessary laparo-
tomy by performing DLS. Findings in the present study
were comparable to those of the other three studies15,17,19
that used DLS in a standardized way.
A good laparoscopic evaluation of the abdominal cavity
in patients with suspicion of colorectal PM not only allows
the exclusion of residual disease and prediction of the
likelihood of complete cytoreduction, thereby avoiding
an unnecessary laparotomy, but also confers several other
advantages. First, DLS allows tissue samples from sus-
picious lesions to be obtained for analysis or cytological
examination. Cytological analysis is gaining in importance,
as positive peritoneal cytology seems to be independently
associated with a poor median OS compared with negative
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cytology25. Biopsies from suspicious lesions can confirm
the presence or absence of peritoneal disease. For example,
in the present cohort, biopsy prevented an unnecessary
laparotomy in 34 patients without colorectal PM (37
per cent). Furthermore, biopsies can provide additional
information for future systemic therapy or identify a
previously unknown primary tumour. Patients who are
deemed unsuitable for CRS+HIPEC because of exten-
sive disease can undergo additional systemic or palliative
chemotherapy at an earlier stage than patients who are still
recovering from a non-therapeutic laparotomy. In patients
who seem suitable for CRS+HIPEC, DLS can provide
more detailed information on the burden and location of
disease before CRS+HIPEC. This can result in a better
informed consent at the outpatient clinic, and may reduce
patient anxiety regarding the exact extent of the procedure.
Finally, it is also possible during DLS to identify patients
who are not fit enough for major surgery.
The present study has some limitations owing to its ret-
rospective design and the fact that all patients came from a
single centre. It is possible that the positive results regard-
ing the visibility of the abdominal cavity during DLS were
due to extensive experience of the HIPEC surgeons in per-
forming DLS in patients with a history of previous abdom-
inal surgery, and may therefore not be extrapolated to all
centres. No patient deemed unsuitable for CRS+HIPEC
during DLS underwent an exploratory laparotomy to con-
firm this assumption. The authors suspect that DLS would
understage rather than overstage the extent of peritoneal
disease in patients with signs of extensive disease. There-
fore, the assumption that a patient is deemed unsuitable
for CRS+HIPEC due to extensive disease would probably
not change during exploratory laparotomy. However, small
peritoneal lesions might be missed during DLS, leading to
a false-negative conclusion. In the present cohort, the like-
lihood of this appeared to be low, as only two of 29 patients
(7 per cent) developed colorectal PMwithin 6months after
a negative DLS.
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